At a glance
ClinicalIndex Comparison RecordPhase 2Active· 51 enrolled
Drug / intervention
Ribociclib +1 moredrug
Likely dose
Ribociclib 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum
In Brief
A Phase 2 clinical trial evaluating Ribociclib and Letrozole for Low Grade Serous Carcinoma. Active but no longer recruiting, targeting 51 participants across 27 sites.
Detailed Summary
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLow Grade Serous Carcinoma
CountriesUnited States
CollaboratorsNovartis
Timeline
Phase 2Active
201920202021202220232024202520262027
First PostedSep 2018
Enrollment StartMay 2019
Primary CompletionDec 2024
TodayJul 2026
Study CompletionDec 2026
First PostedSep 17, 2018
Enrollment StartMay 20, 2019
Primary CompletionDec 23, 2024
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 7.8 years ago
Interventions
Ribociclibdrug
600 mg by mouth daily for 21 days followed by 7 days off treatment
Letrozoledrug
2.5 mg by mouth daily